The disease modifying properties of biological drugs, like peptides, enzymes and antibodies have become well established in the last decades as important medicines. The treatment of brain diseases with these modern treatments is unfortunately hampered by the inability of such drugs to easily pass the blood-brain barrier (BBB).
to-BBB’s G-Technology is designed to transport different classes of drugs across the blood-brain barrier by formulating these drugs into proprietary glutathione coated liposomes. The company has shown proof of concept in different disease models and Genzyme will now evaluate the technology in its disease models.
Geoff McDonough, senior vice president at Genzyme says, "This collaboration will explore an essential component of our work to deliver therapies to the brain, and could further our commitment to patients with neuronopathic disease."
“We look forward to collaborating with Genzyme.” says Willem van Weperen, CEO of to-BBB. “Combining the expertise of Genzyme in neurodegenerative diseases with to-BBB’s brain delivery knowledge, should lead to further progress in treating patients with brain diseases with biological drugs.”
Genzyme is one of the world’s leading biotechnology companies. The company's products and services are focused on rare inherited disorders, kidney disease, orthopedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need. The collaboration with to-BBB could provide Genzyme with an opportunity to improve brain delivery of biological treatments to improve the lives of patients with brain disease.
About to-BBB to-BBB is a Dutch biotechnology company in the field of enhanced drug delivery across the blood-brain barrier. The company is developing novel treatments for brain disorders by combining existing drugs with its proprietary brain drug delivery platform. The company’s vision is that the treatment of currently unserved brain diseases will be best achieved by safely enhancing the blood-to-brain delivery of drugs.
to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.
Contact
Willem van Weperen Chief Executive Officer
Phone: +31 71 3322252 Mobile: +31 634 054812 E-mail: vanweperen@toBBB.com
to-BBB technologies BV Niels Bohrweg 11, 2333 CA Leiden BioScience Park Leiden Bio Partner Center II The Netherlands
www.toBBB.com
